CytoDyn
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (18)
The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)
Started: 6/16/2025
Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
Started: 12/7/2016
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Started: 5/1/2020
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
Started: 11/3/2016
An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study
Started: 8/29/2017
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Started: 4/16/2020
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Started: 3/1/2021
A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation
Started: 5/14/2017
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Started: 4/16/2014
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Started: 12/1/2020
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Started: 9/20/2022
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Started: 4/1/2020
Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140
Started: 10/1/2015
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Started: 12/1/2013
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Started: 3/1/2008
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Started: 4/22/2019